AstraZeneca buys remaining China CAR-T therapy rights from AbelZeta Pharma for $630 M

US-based AbelZeta Pharma, Inc., a global clinicalstage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, has announced that AstraZeneca has agreed to acquire AbelZeta's 50 per cent share of the China development and commercialisation rights to C-CARO31, such that AstraZeneca acquires the sole right to develop, manufacture and commercialise C-CAR031 globally.

- 

Under the terms of the agreement, AbelZeta will be entitled to receive up to $630 million from AstraZeneca including an upfront payment, and development, reg